Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANGER II SFA: Ranger DCB vs Standard Balloon Angioplasty
NCT03064126Phase 3Completed
- Sponsor
- Boston Scientific Corporation
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Countries
- 6
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: Primary Lesion Patency at 12 months and Major Adverse Events at 12 months. Started Mar 2017; status: completed.
Beyond the preview
Go deeper on NCT03064126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064126.